ACTEON acquired by EDMOND DE ROTHSCHILD CAPITAL PARTNERS
Context
Acteon (formerly Satelec-Pierre Rolland), a Mérignac-based medical-dental equipment and consumables manufacturer, has finalized a LBO transaction. Led by Edmond de Rothschild Capital Partners (ERCP) through the special purpose vehicle Financière Noé, the private equity sponsor acquires a 51% controlling interest, while the management team rolls over its equity to retain a 49% stake. Historical shareholders IDI, Edmond de Rothschild Investment Partners (ERIP), and mezzanine provider ICG are converting their stakes into the new structure, facilitating the complete exits of ABN Amro and XAnge Capital. The leveraged financing package comprises a senior debt facility structured across seven tranches and a mezzanine layer. Backed by its strong market positioning, the enterprise is well-placed to leverage its reconstituted investor base to accelerate its high-tech product pipeline and expand its global market presence.
ACTEON, which reported an EBITDA margin of [members only] in 2005, is valued in this transaction at an EV/EBITDA multiple of 5x–12x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Acteon is a France company specialized in Dental Technology. The organization has built its name as a high-fidelity provider of specialized medical devices, particularly leading the field in ultrasound surgery and digital medical imaging. Instead of producing generic dental tools, they thrive on a philosophy of clinical precision, offering innovative hardware that enables dentists and surgeons to perform minimally invasive procedures with superior imaging clarity. Their growth is currently fueled by a rigorous focus on new product development, a shift that has allowed them to break out of historical stagnation and capture significant market share in fast-growing dental tech segments.
Ent. Value
€100–350M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
5x–12x
EV / EBIT
10x–18x
Historical Financials (EUR)
Other operations with ACTEON
Other operations with ACTEON
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
| 08/2012 | BC PARTNERS | AENOVA GROUP | GERMANY | CDMO |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 09/2010 | SPARRING CAPITAL | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 04/2007 | ASTORG | ETHYPHARM | FRANCE | Pharma & Biotech |
REFERENCES
Valuation range: EV €100–350M
Revenue range: €50–100M
EBITDA range: €5–25M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 5x - 12x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ACTEON by EDMOND DE ROTHSCHILD CAPITAL PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Acquirer: edmond de rothschild capital partners